New delivery systems for amphotericin B applied to the improvement of leishmaniasis treatment
AUTOR(ES)
Chávez-Fumagalli, Miguel Angel, Ribeiro, Tatiana Gomes, Castilho, Rachel Oliveira, Fernandes, Simone Odília Antunes, Cardoso, Valbert Nascimento, Coelho, Cecília Steinberg Perilo, Mendonça, Débora Vasconcelos Costa, Soto, Manuel, Tavares, Carlos Alberto Pereira, Faraco, André Augusto Gomes, Coelho, Eduardo Antonio Ferraz
FONTE
Rev. Soc. Bras. Med. Trop.
DATA DE PUBLICAÇÃO
2015-06
RESUMO
Leishmaniasis is one of the six major tropical diseases targeted by the World Health Organization. It is a life-threatening disease of medical, social and economic importance in endemic areas. No vaccine is yet available for human use, and chemotherapy presents several problems. Pentavalent antimonials have been the drugs of choice to treat the disease for more than six decades; however, they exhibit high toxicity and are not indicated for children, for pregnant or breastfeeding women or for chronically ill patients. Amphotericin B (AmpB) is a second-line drug, and although it has been increasingly used to treat visceral leishmaniasis (VL), its clinical use has been hampered due to its high toxicity. This review focuses on the development and in vivo usage of new delivery systems for AmpB that aim to decrease its toxicity without altering its therapeutic efficacy. These new formulations, when adjusted with regard to their production costs, may be considered new drug delivery systems that promise to improve the treatment of leishmaniasis, by reducing the side effects and the number of doses while permitting a satisfactory cost-benefit ratio.
Documentos Relacionados
- Amphotericin B: delivery systems.
- Immunoenhancement Combined with Amphotericin B as Treatment for Experimental Visceral Leishmaniasis
- Efficacious Topical Treatment for Murine Cutaneous Leishmaniasis with Ethanolic Formulations of Amphotericin B
- Treatment of experimental cutaneous leishmaniasis with liposome-intercalated amphotericin B.
- Treatment of mucosal leishmaniasis with amphotericin B lipid complex (ABLC)